Blog

Join SHARE’s Young Professionals Advisory Board!

SHARE is forming an Advisory Board to offer an opportunity for young people to support SHARE's work. Join us for an informational session on August 13 at 6:30pm at SHARE's office, 165 W 46th St., Suite 706 to learn more. Drinks and bites provided. RSVP to our Administrative Manager.

We Run For Hope 2018

Runners and walkers from around the city gathered at Flushing Meadows Park on Sunday, June 4, for the We Run for Hope 5K/10K Run and Walk. This event, held annually on National Cancer Survivors Day, is a great opportunity to support women with breast or ovarian cancer while also staying fit and active.

FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy as a Treatment for Women with Advanced Ovarian Cancer Following Initial Surgery

Avastin is now approved for ten distinct uses across six different types of cancer in the United States.

SOUTH SAN FRANCISCO, Calif. – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.

Most Early-Stage Breast Cancer Patients Can Safely Avoid Chemotherapy, According to Landmark TAILORx Results Presented at ASCO 2018 and Published in The New England Journal of Medicine

Seventy percent of early-stage breast cancer patients can safely forego
chemotherapy and use hormonal therapy alone (such as Arimidex®, tamoxifen or
Faslodex®), according to the long-awaited results of the landmark TAILORx (Trial
Assigning IndividuaLized Options for Treatment (Rx)) study presented at the 2018
American Society of Clinical Oncology (ASCO) Annual Meeting on June 3. The
largest-ever breast cancer treatment study, TAILORx is a prospective, randomized
clinical trial sponsored by the NCI and designed to more precisely define the
effect of chemotherapy for women with Oncotype DX Breast Recurrence Score®
results.

National Helpline:
844-ASK-SHARE